UY30136A1 - Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona - Google Patents

Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona

Info

Publication number
UY30136A1
UY30136A1 UY30136A UY30136A UY30136A1 UY 30136 A1 UY30136 A1 UY 30136A1 UY 30136 A UY30136 A UY 30136A UY 30136 A UY30136 A UY 30136A UY 30136 A1 UY30136 A1 UY 30136A1
Authority
UY
Uruguay
Prior art keywords
derivative
dihydropteridion
anhydra
crystalline form
specific salt
Prior art date
Application number
UY30136A
Other languages
English (en)
Inventor
Dr Matthias Grauert
Rolf Schmid
Dr Peter Sieger
Dr Dr Guenter Linz
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of UY30136A1 publication Critical patent/UY30136A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencinn se refiere a una sal especefica de un derivado de dihidropteridiona, a sab er, la sal de trihidrocloruro del compuesto N-(trans-4-(4-(ciclopropilmetil)-1-piperazinil)ciclohexil)-4-(((7R)-7-etil-5,6,7,8-tetrahidro-5-metil-8-(1-metiletil)-6-oxo-2-pteridinil)amino)-3-metoxi-benzamida, a su cristalizacinn en la forma de un hidratocon agua, a un procedimiento para su fabricacinn y su uso en una composicinn farmaccutica.
UY30136A 2006-02-08 2007-02-08 Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona UY30136A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06101414 2006-02-08

Publications (1)

Publication Number Publication Date
UY30136A1 true UY30136A1 (es) 2007-09-28

Family

ID=38008126

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30136A UY30136A1 (es) 2006-02-08 2007-02-08 Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona

Country Status (22)

Country Link
US (3) US7439358B2 (es)
EP (2) EP2543669A3 (es)
JP (1) JP5134552B2 (es)
KR (2) KR101462879B1 (es)
CN (2) CN102093360B (es)
AR (1) AR059349A1 (es)
AU (1) AU2007213752B2 (es)
BR (1) BRPI0707604A8 (es)
CA (1) CA2635834C (es)
EA (2) EA015389B1 (es)
EC (1) ECSP088589A (es)
HK (2) HK1127772A1 (es)
IL (2) IL193217A (es)
NO (1) NO20082610L (es)
NZ (2) NZ570987A (es)
PE (2) PE20071248A1 (es)
SG (2) SG169397A1 (es)
TW (1) TW200738716A (es)
UA (2) UA101060C2 (es)
UY (1) UY30136A1 (es)
WO (1) WO2007090844A1 (es)
ZA (1) ZA200804587B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004029784A1 (de) * 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) * 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) * 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (de) * 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) * 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004058337A1 (de) * 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
US7439358B2 (en) * 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
RU2009132605A (ru) 2007-02-01 2011-03-10 Астразенека Аб (Se) Производные 5,6,7,8-тетрагидроптеридина в качестве ингибиторов hsp90
WO2009019205A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
EP2610256B1 (en) 2007-09-28 2016-04-27 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
US8598172B2 (en) 2007-12-04 2013-12-03 Nerviano Medical Sciences S.R.L. Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
EP2112152A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Dihydropteridinones as Plk Inhibitors
EP2325185A1 (en) 2009-10-28 2011-05-25 GPC Biotech AG Plk inhibitor
US8445503B2 (en) * 2009-12-23 2013-05-21 Elan Pharmaceuticals, Inc. Inhibitors of polo-like kinase
US8546566B2 (en) * 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20140154304A1 (en) 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib
US20150031699A1 (en) 2013-07-26 2015-01-29 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
BR112015031397A8 (pt) * 2013-07-26 2018-01-30 Boehringer Ingelheim Int volasertib em combinação com decitabine para o tratamento de leucemia mieloide aguda e síndrome mielodisplásica ii.
CN104003989B (zh) * 2014-05-26 2015-11-11 苏州明锐医药科技有限公司 伏拉塞替及其中间体的制备方法
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
CN105646398B (zh) * 2014-12-05 2018-09-07 上海医药工业研究院 N-((1r,4r)-4-(4-(环丙基甲基)哌嗪-1-基)环己基)乙酰胺的制备方法
WO2016206619A1 (zh) * 2015-06-26 2016-12-29 苏州晶云药物科技有限公司 Volasertib及其三盐酸盐的新晶型
WO2019145410A1 (en) 2018-01-25 2019-08-01 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia
TW202404636A (zh) 2022-04-08 2024-02-01 美商英伊布里克斯公司 Dr5促效劑及plk1抑制劑或cdk抑制劑之組合療法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd ６−置換アルコキシ−２−オキソ−１，２−ジヒドロキノキサリン誘導体
DE68908786T2 (de) 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) * 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (es) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) * 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) * 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6096924A (en) 1995-05-19 2000-08-01 Novartis Ag Process for the catalytic hydrogeneration of aromatic nitro compounds
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
JP3887836B2 (ja) * 1995-12-21 2007-02-28 東ソー株式会社 Ｎ−メチルイミダゾール類の製造法
AU720366B2 (en) 1996-09-23 2000-06-01 Eli Lilly And Company Olanzapine dihydrate D
GEP20033029B (en) 1998-08-11 2003-07-25 Pfizer Prod Inc Substituted 1,8-Naphthyridin-4(1H)-Ones as Phosphodiesterase 4 Inhibitors
HUP0202713A3 (en) 1999-09-15 2005-02-28 Warner Lambert Co Pteridinones as kinase inhibitors
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
WO2001070741A1 (en) 2000-03-06 2001-09-27 Warner-Lambert Company 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) * 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
PT1427730E (pt) 2001-09-04 2006-11-30 Boehringer Ingelheim Pharma Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento
PT1908463E (pt) 2001-12-14 2011-12-19 Merck Serono Sa Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
CN1649853A (zh) 2002-05-03 2005-08-03 舍林股份公司 噻唑烷酮类化合物、其制备方法以及作为药物的应用
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
RU2296758C2 (ru) 2002-08-08 2007-04-10 Смитклайн Бичем Корпорейшн Производные тиофена
US20040127504A1 (en) * 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
RS52386B (en) * 2003-02-26 2013-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg. DIHYDROPTERIDINONE, PROCEDURE FOR THEIR PREPARATION AND THEIR APPLICATION AS A MEDICINE
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
US20070134200A1 (en) 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods
CA2522158C (en) 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060035903A1 (en) * 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2008510770A (ja) 2004-08-26 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｌｋ阻害剤としての新規プテリジノン
WO2006021548A1 (de) 2004-08-27 2006-03-02 Boehringer Ingelheim International Gmbh Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1915155A1 (en) 2005-08-03 2008-04-30 Boehringer Ingelheim International GmbH Dihydropteridinones in the treatment of respiratory diseases
EP2340837B1 (en) 2005-11-11 2017-03-15 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
JP2009529038A (ja) 2006-03-07 2009-08-13 アストラゼネカ・アクチエボラーグ ピペリジン誘導体、それらの製造法、治療剤としてのそれらの使用およびそれらを含む医薬組成物
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
WO2009019205A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
JP5841548B2 (ja) 2010-02-17 2016-01-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法及び使用
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors

Also Published As

Publication number Publication date
TW200738716A (en) 2007-10-16
CN102093360B (zh) 2014-11-05
SG169397A1 (en) 2011-03-30
EP2543669A3 (en) 2013-05-15
US8664222B2 (en) 2014-03-04
US20120214995A1 (en) 2012-08-23
JP2009526017A (ja) 2009-07-16
HK1127772A1 (en) 2009-10-09
IL236736A0 (en) 2015-02-26
BRPI0707604A2 (pt) 2011-05-10
NO20082610L (no) 2008-08-26
BRPI0707604A8 (pt) 2017-12-26
EP2543669A2 (en) 2013-01-09
KR101462879B1 (ko) 2014-11-18
EA015389B1 (ru) 2011-08-30
WO2007090844A8 (en) 2007-10-11
ECSP088589A (es) 2008-07-30
US8188086B2 (en) 2012-05-29
PE20110100A1 (es) 2011-02-18
IL193217A0 (en) 2009-02-11
WO2007090844A1 (en) 2007-08-16
EA018663B1 (ru) 2013-09-30
AR059349A1 (es) 2008-03-26
UA101060C2 (ru) 2013-02-25
AU2007213752A1 (en) 2007-08-16
US20070203146A1 (en) 2007-08-30
IL193217A (en) 2017-06-29
KR101445114B1 (ko) 2014-09-29
CN101379064A (zh) 2009-03-04
PE20071248A1 (es) 2008-01-15
SG10201404755SA (en) 2014-10-30
JP5134552B2 (ja) 2013-01-30
CN102093360A (zh) 2011-06-15
CA2635834A1 (en) 2007-08-16
NZ606264A (en) 2014-08-29
CA2635834C (en) 2014-10-21
AU2007213752B2 (en) 2013-01-17
EA200801769A1 (ru) 2009-02-27
US20090030004A1 (en) 2009-01-29
KR20140082837A (ko) 2014-07-02
EP1984367A1 (en) 2008-10-29
HK1158628A1 (en) 2012-07-20
CN101379064B (zh) 2012-01-25
UA95625C2 (ru) 2011-08-25
US7439358B2 (en) 2008-10-21
EA201100638A1 (ru) 2011-10-31
KR20080093068A (ko) 2008-10-17
ZA200804587B (en) 2009-04-29
NZ570987A (en) 2011-09-30

Similar Documents

Publication Publication Date Title
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
BRPI0924183B8 (pt) inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica
AR061024A1 (es) Maleato de 5-amino-3- (2'3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d] pirimidin-2-ona.
CL2007002930A1 (es) Un compuesto 4-[4-({[4-cloro-3-(trifluorometil)fenil]carbamoil}amino)-3-fluorofenoxi]-n-metilpiridin-2-carboxamida monohidratado; proceso de preparacion; composicion y combinacion farmaceutica; y uso para el tratamiento de trastornos hiperproliferati
CL2012001348A1 (es) Sal cristalina de hemitartrato del compuesto genz-112638, inhibidor de glucosilceramida sintetasa; composición farmacéutica que la comprende;y su uso en el tratamiento de la enfermedad de gaucher y enfermedad de fabry.
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
AR052404A1 (es) Hidratos y polimorfos de 4-(((7r)-8-ciclopentil-7-etil-5,6,7,8-tetrahidro-5-metil-6-oxo-2-pteridinil)amino)-3- metoxi-n-(1-metil-4-piperidinil)-benzamida, procedimiento para su preparacion y su uso como farmaco
IL200561A (en) Heterocyclic inhibitors of aspartate protease or their tautomers, their acceptable pharmacy salt, their pharmacy composition and their use
CL2007003805A1 (es) Forma cristalina del compuesto 3-{[5-(acetidin-1-ilcarbonil)piracin-2-il]oxi}-5-[(1-metiletil)oxi]-n-1h-pirazol-3-ilbenzamida; procedimiento de preparacion; composicion farmaceutica que comprende a dicha forma; y uso para el tratamiento de la diabete
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
EA201190296A1 (ru) Дисахариновая, дифумарово-кислая, ди-1-гидрокси-2-нафтойно-кислая и монобензойно-кислая соли 4-(диметиламино)бутил-2-(4-((2-амино-4-метил-6-(пентиламино)пиримидин-5-ил)метил)фенил)ацетата
WO2009021868A3 (en) Novel piperazine amide derivatives
ECSP109890A (es) Particulas de un antagonista de crth2
CL2008002622A1 (es) 1-(1-metiletil)-4-{[4-(tetrahidro-2h-piran-4-iloxi)fenil]carbonil}piperazina y su sal hidrocloruro; formas cristalinas de la sal; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento o profilaxis de deterioro cognitivo, fatiga o trastorno del sueno.
HK1133012A1 (en) Pyrimidinones as casein kinase ii (ck2) modulators
PE20061394A1 (es) Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
HK1112195A1 (en) Substituted oxazole derivatives and their use as tyrosine kinase inhibitors
SMT201300108B (it) Nuove composizioni di 1-Ä2-(2,4-dimetilfenil solfanil)-fenilÜ piperazina
CL2007003042A1 (es) Compuestos derivados del acido tetrahidro-naftalen-1-carboxilico sustituidos con piperidina o piperazina; procedimiento de preparacion; compuesto intermediario; composicion farmaceutica; procedimiento de preparacion; y uso para el tratamiento de arte
WO2009012375A3 (en) Squarate kinase inhibitors
EA201270099A1 (ru) Транс-4-[[(5s)-5-[[[3,5-бис(трифторметил)фенил]метил](2-метил-2h-тетразол-5-ил)амино]-2,3,4,5-тетрагидро-7,9-диметил-1h-1-бензазепин-1-ил]метил]циклогексанкарбоновая кислота
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
ECSP10010150A (es) Forma cristalina 1 de 2-(r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
EA201000701A1 (ru) 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170526